A method of determining the dose of digoxin for heart failure in the modern era

Archives of Internal Medicine

Volumn 166, Issue 22, 2006, Pages 2539-2545

  Bauman, Jerry L ^a   DiDomenico, Robert J ^a   Viana, Marlos ^a,b   Fitch, Melissa ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CREATININE; DIGOXIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSE REGIMEN; FEMALE; HEART FAILURE; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS;

EID: 33845475422     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.22.2539     Document Type: Article

References (22)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:1116-1143.
2. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:10-38.
3. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation. 1995;92:1801-1807.
4. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-878.
5. Adams KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group Trial. J Am Coll Cardiol. 2005;46:497-504.
6. Adams KF, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39:946-953.
7. Terra SG, Washam JB, Dunham GD, Gattis WA. Therapeutic range of digoxin's efficacy in heart failure: what is the evidence? Pharmacotherapy. 1999;19:1123-1126.
8. Bauman JL, DiDomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006;6:77-86.
9. Jelliffe RW. An improved method of digoxin therapy. Ann Intern Med. 1968;69:703-717.
10. Jelliffe RW. A nomogram for digoxin therapy. Am J Med. 1974;57:63-68.
11. Koup JR, Jusko WJ, Elwood CM, Kohl RK. Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther. 1975;18:9-21.
12. Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol. 1974;14:525-535.
13. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
14. Brooker G, Jelliffe RW. Serum cardiac glycoside assay based upon displacement of 3H-oubain from Na-K ATPase. Circulation. 1972;45:20-36.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
16. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650-655.
17. Deming WE. Some Theory of Sampling. New York, NY: Dover; 1950:129.
18. Viana M, Lakshminarayanan V. Dihedral representations and statistical geometric optics, II: elementary instruments. J Mod Opt. In press.
19. Lakshminarayanan V, Viana M. Dihedral representations and statistical geometric optics, I: spherocylindrical lenses. J Opt Soc Am. 2005;22:2483-2489.
20. Afife AA, Azen SP. Statistical Analysis: A Computer Oriented Approach. New York, NY: Academic Press; 1972:113.
21. Ghandi AJ, Vlassess PH, Morton D, Bauman JL. Economic impact of digoxin toxicity. Pharmacoeconomics. 1997;12:175-181.
22. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the Digoxin Intervention Group Trial. J Am Soc Nephrol. 2004;15:2195-2203.